EUCTR2008-001606-16-DE进行中（未招募）1 期
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Pathologically confirmed giant cell tumor of bone within 1 year before study enrollment
- •- Measurable evidence of active disease within 1 year before study enrollment
- •- Subjects with surgically unsalvageable disease (eg, sacral, spinal GCT, or multiple lesions including pulmonary metastases) OR subjects whose planned initial surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity, other than curettage with complete resection of tumor
- •- Karnofsky performance status = 50% (ie, ECOG status 0, 1, or 2)
- •- Adults or skeletally mature adolescents (ie, radiographic evidence of at least 1 mature long bone [eg, humerous with closed growth epiphyseal plate]) = 12 years of age
- •- Skeletally mature adolescents must weigh at least 45 kg
- •- Before any study-specific procedure is performed, the appropriate written informed consent must be obtained.
- •Inclusion Criteria for 20040215 subjects:
- •- Subjects currently enrolled in study 20040215
- •- Before any study-specific procedure is performed, the appropriate written informed consent must be obtained
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 28
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 479
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •- Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization)
- •- Concurrent bisphosphonate treatment
- •- Known or suspected current diagnosis of underlying malignancy including high-grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma
- •- Known or suspected current diagnosis of non GCTB giant cell-rich tumors
- •- Known or suspected current diagnosis of brown cell tumor of bone or Paget’s disease
- •- Known diagnosis of second malignancy within the past 5 years (subjects with definitively treated basal cell carcinoma and cervical
- •carcinoma in situ are permitted)
- •- Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
- •- Active dental or jaw condition which requires oral surgery, including tooth extraction
- •- Non-healed dental/oral surgery
- •- Planned invasive dental procedure for the course of the study
- •- Unstable systemic disease including active infection, uncontrolled
- •hypertension, unstable angina, congestive heart failure, or myocardial
- •infarction within 6 months before enrollment
- •- Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s)
- •- Subject has known sensitivity to any of the products to be administered during dosing
- •- Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before enrollment
- •- Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
- •- Female subject of child bearing potential is not willing to use two methods of highly effective contraception during treatment and for 5 months after the end of treatment
- •- Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
- •Exclusion Criteria for 20040215 subjects:
- •- Developed sensitivity to mammalian cell derived drug products during the 20040215 study
- •- Currently receiving any unapproved investigational product other than
- •- Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
- •- Female subject of child bearing potential is not willing to use two methods of highly effective contraception during treatment and for 5 months after the end of treatment
- •- Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone - Denosumab 20062004Treatment of Giant Cell Tumor (GCT) of BoneMedDRA version: 9.1Level: LLTClassification code 10005970Term: Bone giant cell tumour benignEUCTR2008-001606-16-ITAmgen Inc532
进行中（未招募）
1 期
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone.--------------------------------------------------------Estudio Fase 2, Multicéntrico, Abierto de Denosumab en sujetos con Tumor Óseo de Células GigantesEUCTR2008-001606-16-ESAmgen Ltd100
进行中（未招募）
不适用
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of BoneEUCTR2008-001606-16-Outside-EU/EEAAmgen Inc530
进行中（未招募）
1 期
Denosumab in patients with giant cell rich tumors of bone.Aneurysmal bone cysts, giant cell granuloma, other giant cell rich lesions (primary bone, non-malignant)MedDRA version: 20.1Level: LLTClassification code 10018252Term: Giant cell granuloma peripheralSystem Organ Class: 100000004856MedDRA version: 20.0Level: LLTClassification code 10004430Term: Benign osteoblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008686Term: ChondroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008733Term: Chondromyxoid fibromaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10002362Term: Aneurysmal bone cystSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-005244-42-NLeiden University Medical Center60
进行中（未招募）
1 期
Denosumab in patients with giant cell rich tumors of boneAneurysmal bone cysts, giant cell granuloma, other giant cell rich lesions(primary bone, non-malignant)EUCTR2016-005244-42-FReiden University Medical Center60